

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JAN 2 3 2002

Application of: NI et al.

Application Serial No: 09/512,363

Filed: February 23, 2000

Title: Human Tumor Necrosis Factor

Receptor-Like Proteins TR11, TR11SV1, and TR11SV2

Group Art Unit: 1646

Examiner: Holleran, A.

Atty. Docket No. PF396P1

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 § CFR 1.56

Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to reference C1 listed on the attached revised Form PTO/SB/08A. A copy of reference C1 is enclosed.

Applicants respectfully request that the Examiner review the listed reference and that the reference be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(c)(2), the Patent Office will consider this Second Supplemental Information Disclosure Statement if filed before the mailing date of a final Office Action under 37 C.F.R. §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in this application and accompanied by the fee set forth in § 1.17(p). Accordingly, the required fee of \$180.00 is transmitted herewith with the concurrently filed Fee Transmittal, with the appropriate fee(s).

If any additional fees are deemed necessary, the Patent & Trademark Office is authorized to charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Respectfully submitted,

Dated: JANUARY 23, 2002

Jonathan L. Klein

(Reg. No. 41,119)

Attorney for Applicants

Human Genome Sciences, Inc.

9410 Key West Avenue Rockville, MD 20850 Telephone: (301) 251-6015

Enclosures JKE/MS/vsr